Top in hem/onc: Financial investments, radioligand therapy for prostate cancer

Inflation does not always negatively impact investment strategies. In fact, experts said it is “often welcome.”

The newest investment column from Residency to Retirement was the top story in hematology/oncology last week.

Another top story was about the FDA granting breakthrough therapy designation to a radioligand therapy for advanced prostate cancer. Previous data showed that ¹⁷⁷Lu-PSMA-617 (Novartis) was associated with significantly longer overall survival and radiographic progression-free survival.

Read these and more top stories in hematology/oncology below:

What physicians need to know about inflation

In this column, experts clear up some misconceptions that physicians might have regarding inflation. Read more.

FDA grants breakthrough designation to radioligand therapy for advanced prostate cancer

The FDA granted breakthrough therapy designation to ¹⁷⁷Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer, according to the agent’s manufacturer. Read more.

Use of aggressive, costly end-of-life cancer treatment varies by race, insurance status

An analysis of patients with metastatic cancer revealed higher use of low-value, aggressive and more costly end-of-life interventions for those who belonged to racial or ethnic minority groups, according to retrospective study results. Read more.

Children’s Hospital of Philadelphia again named best hospital for pediatric cancer

Children’s Hospital of Philadelphia has retained its distinction as the No. 1 children’s hospital for cancer in the country. Read more.

ASCO updates guideline for hereditary breast cancer

ASCO issued a guideline update that recommends offering 1-year of adjuvant olaparib (Lynparza, AstraZeneca) to certain patients with breast cancer. Read more.